This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2006 by Zhejiang University.
Recruitment status was:  Recruiting
Information provided by:
Zhejiang University Identifier:
First received: September 5, 2006
Last updated: NA
Last verified: August 2006
History: No changes posted
Experimental data suggest that transplantation of endothelial progenitor cells (EPCs) attenuates monocrotaline-induced pulmonary hypertension in rats and dogs. In addition, clinical studies suggest that autogolous progenitor cells transplantation is feasible and safe in patients with ischemic disease. This study will investigate the feasibility, safety, and initial clinical outcome of intravenous infusion of autologous EPCs in patients with idiopathic pulmonary arterial hypertension.

Condition Intervention
Idiopathic Pulmonary Arterial Hypertension Procedure: Transplantation of autologous endothelial progenitor cells

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Zhejiang University:

Estimated Enrollment: 40
Study Start Date: June 2006
Estimated Study Completion Date: December 2007

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of idiopathic pulmonary arterial hypertension

    1. in New York Heart Association (NYHA) functional class II to III
    2. a mean pulmonary artery pressure more than 30 mmHg on right heart catheterization
    3. the ability to walk ≥50 m during a standardized 6-minute walk test

Exclusion Criteria:

  • Pulmonary hypertension as a result of heart disease, pulmonary disease, sleep-associated disorders, chronic thromboembolic disease, autoimmune or collagen vascular disease, HIV infection, liver disease, NYHA functional class IV, major bleeding requiring blood transfusion, diabetes, renal dysfunction, and evidence for malignant diseases were excluded
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00372346

Contact: xingxiang wang 8657187236500

China, Zhejiang
Department of Cardiology, the First Affiliated Hospital, College of Medicine, Zhejiang University Recruiting
Hangzhou, Zhejiang, China, 310003
Contact: junzhu chen, MD    8657187236889   
Principal Investigator: junhui zhu, MD         
Sponsors and Collaborators
Zhejiang University
Study Chair: junzhu chen, MD the First Affiliated Hospital, College of Medicine, Zhejiang University
  More Information

Publications: Identifier: NCT00372346     History of Changes
Other Study ID Numbers: 419000-X90305
Study First Received: September 5, 2006
Last Updated: September 5, 2006

Additional relevant MeSH terms:
Familial Primary Pulmonary Hypertension
Vascular Diseases
Cardiovascular Diseases
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Diseases processed this record on August 18, 2017